NetworkNewsBreaks – Cerulean Pharma (NASDAQ: CERU) Shares Dive on Stock Purchase Agreement with Daré Bioscience

Shares of Cerulean Pharma (NASDAQ: CERU) dropped 60% this morning after the company said it entered a definitive stock purchase agreement with Daré Bioscience, Inc. under which the equityholders of Daré will become the majority owners of Cerulean. The transaction will result in a public, Nasdaq-listed company focused on the development and commercialization of products for women’s reproductive health. Daré’s product candidate, Ovaprene®, is a clinical stage, non-hormonal contraceptive ring for monthly use that potentially addresses a significant unmet need in the $16 billion global contraception market. The combined company will operate under the name Daré; its CEO will be Sabrina Martucci Johnson, the current CEO of Daré. Cerulean has also entered into two agreements for the sale of assets, including its clinical product candidates, CRLX101 and CRLX301, which were sold for $1.5 million to BlueLink Pharmaceuticals. The company also entered into an agreement with Novartis (NYSE: NVS) through which Novartis will acquire all rights to Cerulean’s Dynamic Tumor Targeting™ Platform for $6 million. The proceeds from these agreements will be used to help fund the combined company’s operations. “Based on Daré’s current projections, with proceeds from the sale of Cerulean’s assets, we believe the combined company will be well funded to advance Ovaprene through the completion of a postcoital proof of concept study that is expected to be a value inflection point and is expected to commence following closing of this transaction,” Cerulean president & chief executive officer Christopher D. T. Guiffre stated in the news release.

To view the full press release, visit: http://nnw.fm/Mh02i

About Cerulean Pharma

Cerulean is a company focused on applying the Dynamic Tumor Targeting™ Platform to create nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body’s normal cells, and enable therapeutic combinations. For more information visit www.ceruleanrx.com.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s